KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查

Proteomic and machine learning analysis predicts treatment response signatures in Myasthenia Gravis.

Karli Gilbert, Amrita K Cheema, Henry J Kaminski, Linda L Kusner

J Transl Med 10.1186/s12967-026-08458-7

PMID42304472
PMCID-
DOI10.1186/s12967-026-08458-7
发表日期2026-06-17
AI 判定该论文不进入自动 KM 提取:This record is not a primary report of a phase III randomized controlled trial. It is a secondary analysis of biomarker data derived from participants in such a trial. The study's primary objective and conclusions are about proteomic signature prediction, not the trial's main clinical endpoints. It falls under the category of a secondary or exploratory analysis, not the report of the trial's results.
摘要

摘要

BACKGROUND: Myasthenia gravis (MG) is a prototypical antibody-mediated autoimmune disease with variable treatment responses with a need for biomarkers to guide therapeutic decision making. Proteomic profiling, coupled with machine learning, offers a hypothesis-free approach to identify multi-protein signatures associated with treatment response. METHODS: We analyzed sera collected at entry (baseline) from participants in a phase 3 trial randomized trial comparing thymectomy plus prednisone versus prednisone alone, along with matched controls using liquid chromatography-mass spectrometry. We derived disease-specific proteomic signatures and evaluated associations between baseline proteins and 6-month clinical outcomes using multiple machine-learning approaches with internal validation. RESULTS: Baseline serum proteomes distinguished MG from controls, with pathway enrichment implicating complement activation, immunoglobulin production, and T-cell receptor signaling. Distinct protein panels predicted 6-month clinical improvement within each treatment arm. In the thymectomy-plus-prednisone group, models captured non-linear relationships of predictive proteins in contrast with the predominant additive patterns observed in the prednisone-alone group. Predictive proteins were enriched for T-cell signaling and leukocyte trafficking functions, providing insight into treatment-specific biology. CONCLUSIONS: Baseline serum proteomics captures core disease characteristics of MG and predicts short-term clinical response in a treatment-specific manner. While our results require validation in independent cohorts, these findings could enable biomarker-guided selection of thymectomy, refine risk stratification, and furnish mechanistic readouts for future MG trials and clinical care. We aim to conduct future studies using -omic approaches to validate these baseline predictive biomarkers and pathways of treatment response in patients with MG.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。